Biotech’s Institutional Memory Crisis

Why Falling Employee Tenure Is Becoming a Major Hiring and Retention Challenge for Biotech Companies

The biotech industry has always been defined by long timelines, specialist expertise and highly collaborative drug development processes. However, a growing workforce trend is beginning to create concern across the sector: employee tenure in biotech is falling rapidly.

Driven by funding pressures, repeated layoffs, retirements and the rise of consulting and fractional leadership roles, biotech companies are seeing shorter employment cycles across scientific, operational and leadership teams. While workforce mobility is not unique to biotech, the consequences may be far greater in an industry where programmes can take more than a decade to reach commercialisation.

As biotech firms continue to prioritise lean operating models and financial efficiency, many are now facing an important strategic question: can companies developing decade-long therapies succeed with increasingly short-term workforces?

Why Employee Tenure in Biotech Is Falling

The decline in average tenure across biotech has been shaped by several overlapping factors over the past few years.

One of the biggest drivers has been the biotech funding slowdown following the post-pandemic market correction. After significant investment activity during 2020 and 2021, many biotech companies were forced to reduce headcount, pause programmes or restructure operations as capital became more difficult to access.

This created widespread instability across the sector, particularly among early-stage and venture-backed biotech companies. Employees who once expected long-term career progression increasingly found themselves navigating repeated restructuring cycles and uncertain funding conditions.

At the same time, many experienced biotech professionals have started moving away from traditional permanent roles altogether. Consulting, advisory work and fractional leadership positions have become increasingly attractive for senior executives, regulatory specialists and clinical operations leaders seeking greater flexibility and reduced exposure to industry volatility.

Retirements are also playing a significant role. Many of the professionals who helped build the modern biotech industry are now approaching retirement age, creating additional pressure on companies already struggling to retain specialist expertise.

According to the OECD, fewer than 50% of workers aged 55–59 remain in the same role after five years across member countries, highlighting broader retention challenges among experienced professionals.

Why Institutional Knowledge Matters in Biotech

High turnover creates challenges in almost every industry, but biotech is uniquely dependent on institutional memory.

Drug development programmes often involve years of accumulated scientific understanding, regulatory interaction and operational coordination. Critical knowledge can sit with individuals who understand:

• previous FDA or EMA feedback
• manufacturing processes
• assay development history
• clinical trial design decisions
• vendor relationships
• safety and compliance considerations

When experienced employees leave, much of this knowledge can disappear with them.

Unlike other sectors where workflows may be easier to standardise, biotech relies heavily on unspoken expertise gained through direct programme involvement. New hires may bring strong technical skills, but rebuilding programme-specific context takes time.

This issue becomes even more important during late-stage development, where continuity can directly influence execution quality, regulatory submissions and manufacturing readiness.

The Hidden Cost of High Employee Turnover

Many biotech organisations still view turnover primarily through the lens of recruitment costs. However, the true operational impact is often much broader.

Frequent employee turnover can lead to:

• delayed programme timelines
• repeated onboarding costs
• reduced cross-functional collaboration
• weaker internal mentorship
• fragmented decision-making
• lower employee morale
• loss of strategic continuity

The challenge is compounded by the increasing use of outsourced and project-based workforce models. While consultants and contract specialists can provide valuable expertise, over-reliance on external talent may reduce long-term organisational cohesion.

This growing dependence on short-term staffing has led some industry leaders to question whether biotech companies are becoming too operationally fragmented.

Funding Pressures Are Reshaping Hiring Strategies

The biotech sector has spent the last several years focused heavily on runway management and operational efficiency. Investors increasingly expect companies to remain lean for longer, particularly during uncertain funding periods.

As a result, many organisations have reduced permanent hiring in favour of smaller internal teams supported by outsourced functions and specialist consultants.

While this approach can reduce fixed costs, it may also increase long-term organisational risk. Drug development requires consistency over many years, yet workforce models are increasingly being built around shorter-term financial cycles.

This tension is beginning to reshape hiring strategies across the sector. Companies are becoming more selective with permanent hires while simultaneously competing for a smaller pool of experienced biotech professionals.

Regulatory Continuity Is Also Becoming a Concern

Institutional continuity is not only a challenge for biotech companies themselves.

Recent leadership turnover within the FDA’s Center for Drug Evaluation and Research has raised concerns about the impact of staff departures on long-term strategic consistency and regulatory oversight.

For biotech companies, this highlights a wider industry reality: continuity matters in highly regulated environments where long-term programme knowledge plays a critical role in decision-making.

Frequent turnover at any stage of the development process can create inefficiencies, communication gaps and increased operational risk.

Why Younger Biotech Professionals Are Changing Career Expectations

The biotech workforce itself is also evolving.

Younger professionals entering the industry today have experienced repeated layoffs, market volatility and shifting hiring conditions. Many no longer expect to spend long periods with a single employer.

Instead, career strategies are increasingly focused on:

• flexibility
• transferable skills
• portfolio careers
• consulting opportunities
• remote working options
• faster progression pathways

This shift in mindset may continue to reduce average tenure across the industry, particularly if companies struggle to rebuild trust following multiple restructuring cycles.

How Specialist Recruitment Agencies Can Help Biotech Companies

As workforce mobility increases, biotech companies may need to rethink how they approach hiring and retention altogether.

Specialist biotech recruitment agencies can provide value beyond simply filling vacancies. Firms with deep industry expertise understand the importance of long-term team stability, technical alignment and cultural fit within highly specialised environments.

A specialist recruitment partner can help biotech companies:

• identify candidates with long-term retention potential
• improve succession planning
• reduce costly hiring mismatches
• access niche scientific and regulatory talent
• build balanced workforce strategies combining permanent and flexible talent

In a market where institutional knowledge is becoming increasingly fragile, hiring decisions have a direct impact on long-term operational performance.

The biotech companies that succeed over the next decade may not simply be those with the strongest pipelines or largest funding rounds, but those able to retain, transfer and build the expertise required to execute consistently over the long timelines that biotech innovation demands.

by Jacob Burrows, Business Lead, Skills Alliance